A citation-based method for searching scientific literature

Gordon C Jayson, Elise C Kohn, Henry C Kitchener, Jonathan A Ledermann. Lancet 2014
Times Cited: 1049







List of co-cited articles
278 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.
Freddie Bray, Jacques Ferlay, Isabelle Soerjomataram, Rebecca L Siegel, Lindsey A Torre, Ahmedin Jemal. CA Cancer J Clin 2018
16

Ovarian cancer statistics, 2018.
Lindsey A Torre, Britton Trabert, Carol E DeSantis, Kimberly D Miller, Goli Samimi, Carolyn D Runowicz, Mia M Gaudet, Ahmedin Jemal, Rebecca L Siegel. CA Cancer J Clin 2018
14

Epithelial ovarian cancer: Evolution of management in the era of precision medicine.
Stephanie Lheureux, Marsela Braunstein, Amit M Oza. CA Cancer J Clin 2019
331
12


Epithelial ovarian cancer.
Stephanie Lheureux, Charlie Gourley, Ignace Vergote, Amit M Oza. Lancet 2019
446
9

Ovarian Cancer: An Integrated Review.
Christine Stewart, Christine Ralyea, Suzy Lockwood. Semin Oncol Nurs 2019
181
8

Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.
Hyuna Sung, Jacques Ferlay, Rebecca L Siegel, Mathieu Laversanne, Isabelle Soerjomataram, Ahmedin Jemal, Freddie Bray. CA Cancer J Clin 2021
8

Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial.
Amit M Oza, Adrian D Cook, Jacobus Pfisterer, Andrew Embleton, Jonathan A Ledermann, Eric Pujade-Lauraine, Gunnar Kristensen, Mark S Carey, Philip Beale, Andrés Cervantes,[...]. Lancet Oncol 2015
409
7

Ovarian cancer.
Ursula A Matulonis, Anil K Sood, Lesley Fallowfield, Brooke E Howitt, Jalid Sehouli, Beth Y Karlan. Nat Rev Dis Primers 2016
382
7

Cancer statistics, 2020.
Rebecca L Siegel, Kimberly D Miller, Ahmedin Jemal. CA Cancer J Clin 2020
7

Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.
Kathleen Moore, Nicoletta Colombo, Giovanni Scambia, Byoung-Gie Kim, Ana Oaknin, Michael Friedlander, Alla Lisyanskaya, Anne Floquet, Alexandra Leary, Gabe S Sonke,[...]. N Engl J Med 2018
978
6

Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial.
Eric Pujade-Lauraine, Felix Hilpert, Béatrice Weber, Alexander Reuss, Andres Poveda, Gunnar Kristensen, Roberto Sorio, Ignace Vergote, Petronella Witteveen, Aristotelis Bamias,[...]. J Clin Oncol 2014
833
6

Cancer Statistics, 2021.
Rebecca L Siegel, Kimberly D Miller, Hannah E Fuchs, Ahmedin Jemal. CA Cancer J Clin 2021
6

Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer.
Ignace Vergote, Claes G Tropé, Frédéric Amant, Gunnar B Kristensen, Tom Ehlen, Nick Johnson, René H M Verheijen, Maria E L van der Burg, Angel J Lacave, Pierluigi Benedetti Panici,[...]. N Engl J Med 2010
5

A phase 3 trial of bevacizumab in ovarian cancer.
Timothy J Perren, Ann Marie Swart, Jacobus Pfisterer, Jonathan A Ledermann, Eric Pujade-Lauraine, Gunnar Kristensen, Mark S Carey, Philip Beale, Andrés Cervantes, Christian Kurzeder,[...]. N Engl J Med 2011
5

Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial.
Eric Pujade-Lauraine, Jonathan A Ledermann, Frédéric Selle, Val Gebski, Richard T Penson, Amit M Oza, Jacob Korach, Tomasz Huzarski, Andrés Poveda, Sandro Pignata,[...]. Lancet Oncol 2017
830
5

Incorporation of bevacizumab in the primary treatment of ovarian cancer.
Robert A Burger, Mark F Brady, Michael A Bookman, Gini F Fleming, Bradley J Monk, Helen Huang, Robert S Mannel, Howard D Homesley, Jeffrey Fowler, Benjamin E Greer,[...]. N Engl J Med 2011
5

Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial.
Jacobus Pfisterer, Catherine M Shannon, Klaus Baumann, Joern Rau, Philipp Harter, Florence Joly, Jalid Sehouli, Ulrich Canzler, Barbara Schmalfeldt, Andrew P Dean,[...]. Lancet Oncol 2020
49
10

Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer.
Isabelle Ray-Coquard, Patricia Pautier, Sandro Pignata, David Pérol, Antonio González-Martín, Regina Berger, Keiichi Fujiwara, Ignace Vergote, Nicoletta Colombo, Johanna Mäenpää,[...]. N Engl J Med 2019
461
5

Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer.
Lin Zhang, Jose R Conejo-Garcia, Dionyssios Katsaros, Phyllis A Gimotty, Marco Massobrio, Giorgia Regnani, Antonis Makrigiannakis, Heidi Gray, Katia Schlienger, Michael N Liebman,[...]. N Engl J Med 2003
5

The biology of ovarian cancer: new opportunities for translation.
Robert C Bast, Bryan Hennessy, Gordon B Mills. Nat Rev Cancer 2009
956
5

Final Overall Survival of a Randomized Trial of Bevacizumab for Primary Treatment of Ovarian Cancer.
Krishnansu S Tewari, Robert A Burger, Danielle Enserro, Barbara M Norquist, Elizabeth M Swisher, Mark F Brady, Michael A Bookman, Gini F Fleming, Helen Huang, Howard D Homesley,[...]. J Clin Oncol 2019
148
4

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).
E A Eisenhauer, P Therasse, J Bogaerts, L H Schwartz, D Sargent, R Ford, J Dancey, S Arbuck, S Gwyther, M Mooney,[...]. Eur J Cancer 2009
4

Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial.
Sean Kehoe, Jane Hook, Matthew Nankivell, Gordon C Jayson, Henry Kitchener, Tito Lopes, David Luesley, Timothy Perren, Selina Bannoo, Monica Mascarenhas,[...]. Lancet 2015
624
4

Epidemiology of ovarian cancer: a review.
Brett M Reid, Jennifer B Permuth, Thomas A Sellers. Cancer Biol Med 2017
521
4

Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial.
Robert L Coleman, Mark F Brady, Thomas J Herzog, Paul Sabbatini, Deborah K Armstrong, Joan L Walker, Byoung-Gie Kim, Keiichi Fujiwara, Krishnansu S Tewari, David M O'Malley,[...]. Lancet Oncol 2017
279
4

Assessment of Combined Nivolumab and Bevacizumab in Relapsed Ovarian Cancer: A Phase 2 Clinical Trial.
Joyce F Liu, Christina Herold, Kathryn P Gray, Richard T Penson, Neil Horowitz, Panagiotis A Konstantinopoulos, Cesar M Castro, Sarah J Hill, Jennifer Curtis, Weixiu Luo,[...]. JAMA Oncol 2019
72
5

ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease†.
N Colombo, C Sessa, A du Bois, J Ledermann, W G McCluggage, I McNeish, P Morice, S Pignata, I Ray-Coquard, I Vergote,[...]. Ann Oncol 2019
274
4

Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer.
Robert L Coleman, Gini F Fleming, Mark F Brady, Elizabeth M Swisher, Karina D Steffensen, Michael Friedlander, Aikou Okamoto, Kathleen N Moore, Noa Efrat Ben-Baruch, Theresa L Werner,[...]. N Engl J Med 2019
315
4

BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group.
Kathryn Alsop, Sian Fereday, Cliff Meldrum, Anna deFazio, Catherine Emmanuel, Joshy George, Alexander Dobrovic, Michael J Birrer, Penelope M Webb, Colin Stewart,[...]. J Clin Oncol 2012
724
4

Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.
Antonio González-Martín, Bhavana Pothuri, Ignace Vergote, René DePont Christensen, Whitney Graybill, Mansoor R Mirza, Colleen McCormick, Domenica Lorusso, Paul Hoskins, Gilles Freyer,[...]. N Engl J Med 2019
544
4

Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer.
David D Bowtell, Steffen Böhm, Ahmed A Ahmed, Paul-Joseph Aspuria, Robert C Bast, Valerie Beral, Jonathan S Berek, Michael J Birrer, Sarah Blagden, Michael A Bookman,[...]. Nat Rev Cancer 2015
552
4

Hallmarks of cancer: the next generation.
Douglas Hanahan, Robert A Weinberg. Cell 2011
4


Bevacizumab Combined With Weekly Paclitaxel, Pegylated Liposomal Doxorubicin, or Topotecan in Platinum-Resistant Recurrent Ovarian Cancer: Analysis by Chemotherapy Cohort of the Randomized Phase III AURELIA Trial.
Andres M Poveda, Frédéric Selle, Felix Hilpert, Alexander Reuss, Antonella Savarese, Ignace Vergote, Petronella Witteveen, Aristotelis Bamias, Nana Scotto, Lada Mitchell,[...]. J Clin Oncol 2015
106
4

Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial.
Ian J Jacobs, Usha Menon, Andy Ryan, Aleksandra Gentry-Maharaj, Matthew Burnell, Jatinderpal K Kalsi, Nazar N Amso, Sophia Apostolidou, Elizabeth Benjamin, Derek Cruickshank,[...]. Lancet 2016
517
4


Cancer statistics, 2016.
Rebecca L Siegel, Kimberly D Miller, Ahmedin Jemal. CA Cancer J Clin 2016
3

High grade serous ovarian carcinomas originate in the fallopian tube.
S Intidhar Labidi-Galy, Eniko Papp, Dorothy Hallberg, Noushin Niknafs, Vilmos Adleff, Michael Noe, Rohit Bhattacharya, Marian Novak, Siân Jones, Jillian Phallen,[...]. Nat Commun 2017
284
3

Distinct evolutionary trajectories of primary high-grade serous ovarian cancers revealed through spatial mutational profiling.
Ali Bashashati, Gavin Ha, Alicia Tone, Jiarui Ding, Leah M Prentice, Andrew Roth, Jamie Rosner, Karey Shumansky, Steve Kalloger, Janine Senz,[...]. J Pathol 2013
272
3

Efficacy and safety of bevacizumab-containing neoadjuvant therapy followed by interval debulking surgery in advanced ovarian cancer: Results from the ANTHALYA trial.
Roman Rouzier, Sébastien Gouy, Frédéric Selle, Eric Lambaudie, Anne Floquet, Virginie Fourchotte, Christophe Pomel, Pierre-Emmanuel Colombo, Elsa Kalbacher, Sandrine Martin-Francoise,[...]. Eur J Cancer 2017
46
6

Neoadjuvant chemotherapy versus debulking surgery in advanced tubo-ovarian cancers: pooled analysis of individual patient data from the EORTC 55971 and CHORUS trials.
Ignace Vergote, Corneel Coens, Matthew Nankivell, Gunnar B Kristensen, Mahesh K B Parmar, Tom Ehlen, Gordon C Jayson, Nick Johnson, Ann Marie Swart, René Verheijen,[...]. Lancet Oncol 2018
103
3

Chemotherapy Response Score: Development and Validation of a System to Quantify Histopathologic Response to Neoadjuvant Chemotherapy in Tubo-Ovarian High-Grade Serous Carcinoma.
Steffen Böhm, Asma Faruqi, Ian Said, Michelle Lockley, Elly Brockbank, Arjun Jeyarajah, Amanda Fitzpatrick, Darren Ennis, Thomas Dowe, Jennifer L Santos,[...]. J Clin Oncol 2015
129
3



Exosomal transfer of stroma-derived miR21 confers paclitaxel resistance in ovarian cancer cells through targeting APAF1.
Chi Lam Au Yeung, Ngai-Na Co, Tetsushi Tsuruga, Tsz-Lun Yeung, Suet-Ying Kwan, Cecilia S Leung, Yong Li, Edward S Lu, Kenny Kwan, Kwong-Kwok Wong,[...]. Nat Commun 2016
410
3

An evolving story of the metastatic voyage of ovarian cancer cells: cellular and molecular orchestration of the adipose-rich metastatic microenvironment.
Takeshi Motohara, Kenta Masuda, Matteo Morotti, Yiyan Zheng, Salma El-Sahhar, Kay Yi Chong, Nina Wietek, Abdulkhaliq Alsaadi, Mohammad Karaminejadranjbar, Zhiyuan Hu,[...]. Oncogene 2019
71
4

NCCN Guidelines Insights: Ovarian Cancer, Version 1.2019.
Deborah K Armstrong, Ronald D Alvarez, Jamie N Bakkum-Gamez, Lisa Barroilhet, Kian Behbakht, Andrew Berchuck, Jonathan S Berek, Lee-May Chen, Mihaela Cristea, Marie DeRosa,[...]. J Natl Compr Canc Netw 2019
105
3


OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer.
Carol Aghajanian, Stephanie V Blank, Barbara A Goff, Patricia L Judson, Michael G Teneriello, Amreen Husain, Mika A Sovak, Jing Yi, Lawrence R Nycum. J Clin Oncol 2012
818
3


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.